|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ANKRD11 |
Gene summary for ANKRD11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ANKRD11 | Gene ID | 29123 |
| Gene name | ankyrin repeat domain 11 | |
| Gene Alias | ANCO-1 | |
| Cytomap | 16q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q6UB99 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29123 | ANKRD11 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 2.89e-03 | 4.11e-01 | 0.1604 |
| 29123 | ANKRD11 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 4.57e-04 | 1.16e-01 | 0.1602 |
| 29123 | ANKRD11 | GSM5353228_PA_PR5199-640K_Pool_1_3_S108_L004 | Human | Prostate | Tumor | 1.69e-03 | 8.09e-02 | 0.1537 |
| 29123 | ANKRD11 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 5.01e-03 | 3.35e-01 | 0.1608 |
| 29123 | ANKRD11 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 3.20e-14 | 4.94e-01 | 0.1575 |
| 29123 | ANKRD11 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 4.51e-23 | 3.21e-01 | 0.1545 |
| 29123 | ANKRD11 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 3.07e-20 | 4.70e-01 | 0.1569 |
| 29123 | ANKRD11 | GSM5353247_PA_PR5269_3_S27_L002 | Human | Prostate | Tumor | 1.69e-02 | -1.20e-01 | 0.1532 |
| 29123 | ANKRD11 | GSM5353248_PA_PR5269_4_S28_L002 | Human | Prostate | Tumor | 3.25e-09 | 3.70e-01 | 0.1541 |
| 29123 | ANKRD11 | P1_S1_AK | Human | Skin | AK | 6.99e-26 | 6.94e-01 | -0.3399 |
| 29123 | ANKRD11 | P2_S3_AK | Human | Skin | AK | 2.49e-17 | 5.68e-01 | -0.3287 |
| 29123 | ANKRD11 | P3_S6_AK | Human | Skin | AK | 8.27e-06 | 4.34e-01 | -0.3256 |
| 29123 | ANKRD11 | P4_S8_cSCC | Human | Skin | cSCC | 2.66e-11 | 4.19e-01 | -0.3095 |
| 29123 | ANKRD11 | P5_S10_cSCC | Human | Skin | cSCC | 5.50e-30 | 5.86e-01 | -0.299 |
| 29123 | ANKRD11 | P1_cSCC | Human | Skin | cSCC | 1.28e-23 | 9.96e-01 | 0.0292 |
| 29123 | ANKRD11 | P2_cSCC | Human | Skin | cSCC | 1.41e-08 | 5.16e-01 | -0.024 |
| 29123 | ANKRD11 | P4_cSCC | Human | Skin | cSCC | 2.70e-08 | 5.48e-01 | -0.00290000000000005 |
| 29123 | ANKRD11 | P10_cSCC | Human | Skin | cSCC | 1.56e-09 | 7.01e-01 | 0.1017 |
| 29123 | ANKRD11 | cSCC_p8 | Human | Skin | cSCC | 7.55e-03 | 5.44e-02 | -0.1971 |
| 29123 | ANKRD11 | Pat01-B | Human | Stomach | GC | 2.41e-41 | 7.89e-01 | 0.5754 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0048705 | Colorectum | CRC | skeletal system morphogenesis | 37/2078 | 220/18723 | 6.58e-03 | 4.71e-02 | 37 |
| GO:00603242 | Esophagus | ESCC | face development | 34/8552 | 44/18723 | 1.90e-05 | 1.67e-04 | 34 |
| GO:00101711 | Esophagus | ESCC | body morphogenesis | 30/8552 | 43/18723 | 1.21e-03 | 5.88e-03 | 30 |
| GO:00603253 | Esophagus | ESCC | face morphogenesis | 21/8552 | 28/18723 | 1.57e-03 | 7.33e-03 | 21 |
| GO:00487052 | Esophagus | ESCC | skeletal system morphogenesis | 120/8552 | 220/18723 | 4.90e-03 | 1.89e-02 | 120 |
| GO:00603232 | Esophagus | ESCC | head morphogenesis | 22/8552 | 32/18723 | 7.12e-03 | 2.58e-02 | 22 |
| GO:0060325 | Liver | NAFLD | face morphogenesis | 8/1882 | 28/18723 | 5.07e-03 | 3.96e-02 | 8 |
| GO:0060324 | Oral cavity | OSCC | face development | 28/7305 | 44/18723 | 8.15e-04 | 4.35e-03 | 28 |
| GO:00603252 | Oral cavity | OSCC | face morphogenesis | 18/7305 | 28/18723 | 5.96e-03 | 2.27e-02 | 18 |
| GO:0060323 | Oral cavity | OSCC | head morphogenesis | 19/7305 | 32/18723 | 1.56e-02 | 5.00e-02 | 19 |
| GO:00603241 | Oral cavity | NEOLP | face development | 16/2005 | 44/18723 | 6.27e-06 | 1.26e-04 | 16 |
| GO:00603231 | Oral cavity | NEOLP | head morphogenesis | 12/2005 | 32/18723 | 6.38e-05 | 8.40e-04 | 12 |
| GO:00603251 | Oral cavity | NEOLP | face morphogenesis | 11/2005 | 28/18723 | 7.84e-05 | 1.00e-03 | 11 |
| GO:0010171 | Oral cavity | NEOLP | body morphogenesis | 14/2005 | 43/18723 | 9.66e-05 | 1.18e-03 | 14 |
| GO:00487051 | Oral cavity | NEOLP | skeletal system morphogenesis | 36/2005 | 220/18723 | 6.47e-03 | 3.33e-02 | 36 |
| GO:00603254 | Skin | AK | face morphogenesis | 10/1910 | 28/18723 | 2.78e-04 | 2.94e-03 | 10 |
| GO:00101712 | Skin | AK | body morphogenesis | 12/1910 | 43/18723 | 9.25e-04 | 7.53e-03 | 12 |
| GO:00603233 | Skin | AK | head morphogenesis | 10/1910 | 32/18723 | 9.35e-04 | 7.56e-03 | 10 |
| GO:00603243 | Skin | AK | face development | 12/1910 | 44/18723 | 1.16e-03 | 8.88e-03 | 12 |
| GO:00603244 | Thyroid | PTC | face development | 24/5968 | 44/18723 | 1.52e-03 | 8.49e-03 | 24 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ANKRD11 | SNV | Missense_Mutation | c.4129N>T | p.Gly1377Cys | p.G1377C | Q6UB99 | protein_coding | deleterious(0.01) | benign(0.43) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD | |
| ANKRD11 | SNV | Missense_Mutation | c.3844N>A | p.Glu1282Lys | p.E1282K | Q6UB99 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.906) | TCGA-A2-A0SX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD | |
| ANKRD11 | SNV | Missense_Mutation | c.907G>A | p.Glu303Lys | p.E303K | Q6UB99 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| ANKRD11 | SNV | Missense_Mutation | novel | c.1042N>A | p.Glu348Lys | p.E348K | Q6UB99 | protein_coding | deleterious(0.01) | probably_damaging(0.965) | TCGA-A7-A5ZW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| ANKRD11 | SNV | Missense_Mutation | c.5149N>A | p.Glu1717Lys | p.E1717K | Q6UB99 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ANKRD11 | SNV | Missense_Mutation | c.4737N>A | p.Met1579Ile | p.M1579I | Q6UB99 | protein_coding | deleterious(0) | benign(0.041) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ANKRD11 | SNV | Missense_Mutation | c.461N>T | p.Ala154Val | p.A154V | Q6UB99 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ANKRD11 | SNV | Missense_Mutation | c.1571N>T | p.Ser524Leu | p.S524L | Q6UB99 | protein_coding | deleterious(0.01) | probably_damaging(0.945) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ANKRD11 | SNV | Missense_Mutation | c.2150N>T | p.Ser717Leu | p.S717L | Q6UB99 | protein_coding | tolerated(0.06) | benign(0.035) | TCGA-AO-A1KS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| ANKRD11 | SNV | Missense_Mutation | c.3172N>C | p.Glu1058Gln | p.E1058Q | Q6UB99 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.69) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |